Terms: = Ovarian cancer AND EZH2, ENX-1, 2146, ENSG00000106462, Q15910, MGC9169
144 results:
1. Iron overload increases the sensitivity of endometriosis stromal cells to ferroptosis via a PRC2-independent function of ezh2.
Luo Y; Li L; Hu Q; Zhang Z; Liu F; Peng Y; Zou Y; Chen L
Int J Biochem Cell Biol; 2024 Apr; 169():106553. PubMed ID: 38417568
[TBL] [Abstract] [Full Text] [Related]
2. ezh2-mediated development of therapeutic resistance in cancer.
Kaur P; Shankar E; Gupta S
Cancer Lett; 2024 Apr; 586():216706. PubMed ID: 38331087
[TBL] [Abstract] [Full Text] [Related]
3. MAPRE3 as an epigenetic target of ezh2 restricts ovarian cancer proliferation in vitro and in vivo.
Zhang Y; Liu F; Zheng J; Jiang K; Ai H; Liu L; Mao D
Exp Cell Res; 2024 Feb; 435(1):113913. PubMed ID: 38199479
[TBL] [Abstract] [Full Text] [Related]
4. Dual target PARP1/ezh2 inhibitors inducing excessive autophagy and producing synthetic lethality for triple-negative breast cancer therapy.
Li X; Wang C; Li S; Yin F; Luo H; Zhang Y; Luo Z; Chen Y; Wan S; Kong L; Wang X
Eur J Med Chem; 2024 Feb; 265():116054. PubMed ID: 38134746
[TBL] [Abstract] [Full Text] [Related]
5. Underrepresentation of racial and ethnic minority groups in gynecologic oncology: An analysis of over 250 trials.
Richardson MT; Barry D; Steinberg JR; Thirunavu V; Strom DE; Holder K; Zhang N; Turner BE; Magnani CJ; Weeks BT; Young AMP; Lu CF; Wolgemuth TR; Laasiri N; Squires NA; Anderson JN; Karlan BY; Chan JK; Kapp DS; Roque DR; Salani R
Gynecol Oncol; 2024 Feb; 181():1-7. PubMed ID: 38096673
[TBL] [Abstract] [Full Text] [Related]
6. ezh2 Contributes to Anoikis Resistance and Promotes Epithelial ovarian cancer Peritoneal Metastasis by Regulating m6A.
Wang SH; Liu L; Bao KY; Zhang YF; Wang WW; Du S; Jia NE; Suo S; Cai J; Guo JF; Lv G
Curr Med Sci; 2023 Aug; 43(4):794-802. PubMed ID: 37498408
[TBL] [Abstract] [Full Text] [Related]
7. ezh2 mediated metabolic rewiring promotes tumor growth independently of histone methyltransferase activity in ovarian cancer.
Chen J; Hong JH; Huang Y; Liu S; Yin J; Deng P; Sun Y; Yu Z; Zeng X; Xiao R; Chan JY; Guan P; Wang Y; Wang P; Liu L; Wen S; Yu Q; Ong CK; Teh BT; Xiong Y; Tan J
Mol Cancer; 2023 May; 22(1):85. PubMed ID: 37210576
[TBL] [Abstract] [Full Text] [Related]
8. Pharmacological inhibition of ezh2 using a covalent inhibitor suppresses human ovarian cancer cell migration and invasion.
Shi L; Zhang Q; Zhu S; Tang Q; Chen X; Lan R; Wang N; Zhu Y
Mol Cell Biochem; 2024 Apr; 479(4):831-841. PubMed ID: 37199893
[TBL] [Abstract] [Full Text] [Related]
9. Epigenetic reactivation of PEG3 by ezh2 inhibitors suppresses renal clear cell carcinoma progress.
Qiu T; Ding Y; Qin J; Ren D; Xie M; Qian Q; Wang Y; Ma L; Jing A; Yang J; Ma S; Wang X; Wang W; Ji J; Li G
Cell Signal; 2023 Jul; 107():110662. PubMed ID: 37001595
[TBL] [Abstract] [Full Text] [Related]
10. LncRNA SLC25A21-AS1 increases the chemosensitivity and inhibits the progression of ovarian cancer by upregulating the expression of KCNK4.
Huang K; Chen X; Geng Z; Xiong X; Cong Y; Pan X; Liu S; Ge L; Xu J; Jia X
Funct Integr Genomics; 2023 Mar; 23(2):110. PubMed ID: 36995496
[TBL] [Abstract] [Full Text] [Related]
11. Differential effects of the LncRNA RNF157-AS1 on epithelial ovarian cancer cells through suppression of DIRAS3- and ULK1-mediated autophagy.
Xu P; Xu S; Pan H; Dai C; Xu Y; Wang L; Cong Y; Zhang H; Cao J; Ge L; Jia X
Cell Death Dis; 2023 Feb; 14(2):140. PubMed ID: 36805591
[TBL] [Abstract] [Full Text] [Related]
12. Discovery of a Novel Covalent ezh2 Inhibitor Based on Tazemetostat Scaffold for the Treatment of ovarian cancer.
Zhang Q; Chen X; Cao J; Yang W; Wan G; Feng Q; Zhou S; Yang H; Wang N; Liu Z; Xiao H; Zhu Y; Yu L
J Med Chem; 2023 Feb; 66(3):1725-1741. PubMed ID: 36692394
[TBL] [Abstract] [Full Text] [Related]
13. The epigenetic factor CHD4 contributes to metastasis by regulating the ezh2/β-catenin axis and acts as a therapeutic target in ovarian cancer.
Wang J; Zhong F; Li J; Yue H; Li W; Lu X
J Transl Med; 2023 Jan; 21(1):38. PubMed ID: 36681835
[TBL] [Abstract] [Full Text] [Related]
14. Expanding the molecular spectrum of gene fusions in endometrial stromal sarcoma: Novel subunits of the chromatin remodeling complexes PRC2 and NuA4/TIP60 as alternative fusion partners.
Dermawan JK; Dashti N; Chiang S; Turashvili G; Dickson BC; Ellenson LH; Kirchner M; Stenzinger A; Mechtersheimer G; Agaimy A; Antonescu CR
Genes Chromosomes Cancer; 2023 Mar; 62(3):152-160. PubMed ID: 36445224
[TBL] [Abstract] [Full Text] [Related]
15. H3K27me3 in Diffuse Midline Glioma and Epithelial ovarian cancer: Opposing Epigenetic Changes Leading to the Same Poor Outcomes.
Day CA; Hinchcliffe EH; Robinson JP
Cells; 2022 Oct; 11(21):. PubMed ID: 36359771
[TBL] [Abstract] [Full Text] [Related]
16. Distinct roles of treatment schemes and BRCA2 on the restoration of homologous recombination DNA repair and PARP inhibitor resistance in ovarian cancer.
Huang TT; Burkett SS; Tandon M; Yamamoto TM; Gupta N; Bitler BG; Lee JM; Nair JR
Oncogene; 2022 Nov; 41(46):5020-5031. PubMed ID: 36224341
[TBL] [Abstract] [Full Text] [Related]
17. FBP1 knockdown decreases ovarian cancer formation and cisplatin resistance through ezh2-mediated H3K27me3.
Xiong X; Lai X; Zhang J; Meng Q; Wang P; Qin S; Liu W; Wang Y; Yao Z; Wang D; Li X; Liu Z; Miao H
Biosci Rep; 2022 Sep; 42(9):. PubMed ID: 36000567
[TBL] [Abstract] [Full Text] [Related]
18. CRABP2 accelerates epithelial mesenchymal transition in serous ovarian cancer cells by promoting TRIM16 methylation via upregulating ezh2 expression.
Xie T; Tan M; Gao Y; Yang H
Environ Toxicol; 2022 Aug; 37(8):1957-1967. PubMed ID: 35442568
[TBL] [Abstract] [Full Text] [Related]
19. Dual G9A/ezh2 Inhibition Stimulates Antitumor Immune Response in ovarian High-Grade Serous Carcinoma.
Spiliopoulou P; Spear S; Mirza H; Garner I; McGarry L; Grundland-Freile F; Cheng Z; Ennis DP; Iyer N; McNamara S; Natoli M; Mason S; Blyth K; Adams PD; Roxburgh P; Fuchter MJ; Brown B; McNeish IA
Mol Cancer Ther; 2022 Apr; 21(4):522-534. PubMed ID: 35131874
[TBL] [Abstract] [Full Text] [Related]
20. Targeting ARID1A mutations in cancer.
Mullen J; Kato S; Sicklick JK; Kurzrock R
Cancer Treat Rev; 2021 Nov; 100():102287. PubMed ID: 34619527
[TBL] [Abstract] [Full Text] [Related]
[Next]
